Moshe 'Mori' Arkin is an Israeli businessman, the self-made billionaire Founder and Chairman of Arkin Holdings, a major investment firm focused on pharmaceuticals and life sciences. Born in Ramat Gan, Israel, in 1952, his career is rooted in military service, psychology, and biomedical entrepreneurship.

Arkin took over the family business, Agis Industries, at age 19 after the sudden death of his father, Ziama Arkin. He holds an undergraduate degree in Psychology and Philosophy from Tel Aviv University. His philosophical approach centers on technological foresight, operational efficiency, and high-impact medical philanthropy (focusing on cancer and immunology).

• Agis Industries (Former Owner): The foundational source of his wealth, a major generic and dermatological pharmaceutical company (sold to Perrigo for $390 million in 2005).
• Arkin Holdings (Founder & Chairman): The core private asset, a major investment firm focused on life sciences, pharmaceuticals, and medical equipment (managing $1 billion+ in assets).
• Investment Apex: He is known for taking a controlling stake in Bezeq Telecommunications and founding the Accelmed Fund (healthcare VC).
• Philanthropy: He founded the Morris Kahn Initiative for Cancer Research and funds the Arkin Family Foundation (supporting education, arts, and Jewish-Arab coexistence).

Mori Arkin's strategic genius was his commitment to generic drugs and international expansion. He assumed leadership of Agis Industries at a young age, successfully growing it into a major force in dermatological and generic pharmaceuticals before selling it to Perrigo for $390 million in 2005.

Following the exit, he founded Arkin Holdings in 2009, pivoting his focus to venture investment in Israeli life sciences and biotech (often co-founding companies). His structural contribution is immense: funding foundational cancer and immunology research (e.g., the Morris Kahn Initiative at Tel Aviv University). His wealth is secured by the colossal liquid gains from the Agis sale and the long-term appreciation of his life sciences investment portfolio.

Mori Arkin's social impact is massive and structural, stemming from his commitment to advancing medical research in Israel. His Morris Kahn Initiative funds pioneering cancer research (e.g., 3D cancer modeling) at Tel Aviv University. His Arkin Family Foundation provides major structural support for education, arts, and Jewish-Arab coexistence in Israel. His early work also established pharmaceutical manufacturing facilities that created jobs in the Negev.

His structural contribution is tied to his belief in scientific rigor and leveraging private capital to solve complex public health challenges.

Mori Arkin maintains the professional, composed style of a corporate executive. His attire is consistently formal and high-quality, favoring tailored suits. His aesthetic reflects serious authority and intellectual depth, typical of a leader in the specialized life sciences sector.

Residing in Tel Aviv, Israel, his luxury is the immense security and financial reward derived from his multi-billion dollar fortune. His life is dedicated to investment strategy, medical research, and cultural patronage.